UAE Launches Next-Gen GPS-Less Navigation and Secure Flight Control to Strengthen Aviation Security
18.2.2025 14:19:00 CET | Business Wire | Press release
VentureOne and ADASI Partner to Integrate Advanced Autonomous Flight Technologies Powered by TII – Perceptra and Saluki Unveiled at IDEX 2025
As dual-use technologies increasingly drive economies of scale worldwide, ADASI, a leader in UAV system manufacturing, has announced their adoption of two advanced autonomous flight technologies by Abu Dhabi’s VentureOne: Perceptra, a new cutting-edge GPS-less navigation technology, and Saluki, a high-security flight control technology for autonomous systems.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218620933/en/

UAE Launches Next-Gen GPS-Less Navigation and Secure Flight Control to Strengthen Aviation Security (Photo: AETOSWire)
These technologies, both developed by the Technology Innovation Institute, are designed to deliver secure, resilient operations in the most challenging environments. They have been optimized for UAV manufacturers, offering enhanced resilience, precision, and security for autonomous aerial operations. The agreement between VentureOne, ADASI, and TII was formalized at IDEX 2025, the Middle East’s largest defense exhibition, at which Saluki and Perceptra were unveiled.
Global Positioning System (GPS) technology has long been a fundamental pillar of navigation, supporting applications from everyday smartphone use to critical defense and military operations. However, this widespread reliance on GPS has exposed vulnerabilities that can be exploited through techniques like jamming and spoofing. Jamming occurs when signals on the same frequency overwhelm GPS receivers, preventing accurate location tracking, while spoofing involves transmitting counterfeit signals to deceive receivers into calculating incorrect positions or times. These vulnerabilities pose significant risks across sectors that depend on precise navigation, including autonomous drones, commercial aviation, and military aircraft.
In defense and security, compromised GPS signals can impact mission success and personnel safety, while in aviation, navigation errors may cause flight path deviations and operational disruptions – reports of which have the aviation industry and international regulators such as IATA and European regulator EASA seeking urgent solutions for GPS interference, according to one Reuters report in 2024.
For autonomous systems like drones and self-driving vehicles, the inability to maintain accurate positioning can create safety hazards, particularly in dynamic or high-risk environments, from aviation to defense. As the use of GPS-dependent systems continues to grow, the need for resilient, alternative navigation solutions has become increasingly critical. Perceptra and Saluki overcome many of today’s numerous challenges with advanced vision-based navigation, delivering reliable, resilient performance.
Dr. Najwa Aaraj, CEO of TII, said, “Perceptra, with its GPS-less capabilities, and Saluki, with its sophisticated Zero Trust architecture, represent a significant leap in autonomous navigation with the potential to transform multiple sectors. From supporting safe travel in commercial flights, search-and-rescue missions with precise navigation, to enabling efficient urban drone logistics for deliveries in densely populated cities, these technologies have broad real-world applications. Their adaptability also makes them invaluable in defense, ensuring secure and resilient operations in even the most challenging environments. This collaboration reflects our commitment to developing advanced, dual-use technologies that serve both civilian and defense needs while positioning the UAE as a leader in next-generation autonomous systems.”
Perceptra is a vision-based system that ensures reliable navigation without GPS, allowing aerial platforms to operate in GNSS-denied environments. It features visual relocking, low navigation errors, and easy integration across platforms for intelligence, surveillance, reconnaissance, and electronic warfare.
Saluki is a secure, high-performance flight controller and mission computer with Zero Trust architecture. With PX4 compatibility, Gen AI capabilities, and 300 TOPS compute power, it supports multi-vehicle management for mission-critical defense applications.
“At ADASI, we integrate only the most advanced, field-proven technologies to ensure our UAVs operate with unmatched precision, resilience, and security, even in the most contested environments,” said Juma Al Kaabi, the CEO of ADASI. “Perceptra and Saluki provide exactly what next-generation UAVs require: secure, GPS-independent navigation and AI-powered mission control.”
“VentureOne is dedicated to ensuring that cutting-edge research becomes reality to make a positive impact and transform industries,” said Reda Nidhakou, the Acting CEO of VentureOne. “Saluki and Perceptra are just two of many new innovations to come that will help ensure more resilient and safer drone operations in different sectors, starting with defense. We are working on a more comprehensive air autonomy and security portfolio that will play a central role in future drone operations.”
Last week, TII announced its collaboration with the General Civil Aviation Authority (GCAA) to support regulatory efforts by developing advanced methodologies for air corridor design. These methodologies aim to optimize flight routes and reduce the risk of aerial incidents in complex urban airspaces, ensuring safe and efficient navigation for both piloted and autonomous drone taxis. These efforts, alongside Perceptra and Saluki, reinforce Abu Dhabi’s vision to lead in next-generation navigation and AI-powered autonomy.
Both VentureOne and TII are part of the Advanced Technology Research Council (ATRC), which oversees Abu Dhabi’s research and development ecosystem to advance transformative technologies with global impact. ADASI is part of the EDGE Group, the advanced technology and defense conglomerate.
Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20250218620933/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom